iBio

iBio Net Debt / EBITDA

The Net Debt to EBITDA of iBio (IBIO) as of Nov 17, 2026 is 2.44. In the previous year, Net Debt to EBITDA was 0.27 — a change of 795.55% (higher).

Net Debt / EBITDA

2.44

YoY

795.55%

Last updated:

Net Debt to EBITDA of iBio is 2026 2.44 . Net Debt to EBITDA of iBio was 2025 0.27 . It decreases by 795.55% higher compared to the previous year.

The iBio Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2019
-1.32 USD
Jan 1, 2020
1.62 USD
Jan 1, 2021
2.08 USD
Jan 1, 2022
0.26 USD
Jan 1, 2023
-0.33 USD
Jan 1, 2024
0.59 USD
Jan 1, 2025
0.27 USD
Jan 1, 2026
2.44 USD
The iBio Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
2.44+795.55%
0.27-53.46%
0.59-276.25%
-0.33-227.35%
0.26-87.47%
2.08+28.56%
1.62-222.45%
-1.32+100.78%
-0.66-45.44%
-1.21+393.95%
-0.24-117.18%
1.42+38.06%
1.03+153.42%
0.41-25.62%
0.55—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iBio Stock analysis

What does iBio do? iBio, Inc. generates revenue through the commercialization of its plant-based protein expression technologies, which are used for developing vaccines and therapeutic proteins. The company's iBioLaunch technology and iBioModulator platform enable the production of biologics in hydroponically grown green plants, targeting fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of plasma-derived products. Clients and collaborators purchase product development and manufacturing services, leveraging iBio's transformative platform for biologics production. The firm focuses on both its own product candidates and providing services to external partners in the biopharmaceutical sector. iBio's business model centers on offering its proprietary technologies as a service to clients, with a focus on developing and manufacturing biologics through plant-based systems. The company's technologies are applicable across multiple therapeutic areas, including fibrotic disease treatments, vaccine development, and enzyme replacement therapies. By providing these services, iBio supports clients in creating advanced biopharmaceutical products without the need for traditional manufacturing infrastructure. The company's revenue streams include the sale of its iBioLaunch and iBioModulator platforms, as well as product development and manufacturing services for biopharmaceutical clients. These services are tailored to meet the needs of partners seeking efficient, scalable production methods for biologics. iBio's focus on plant-based production differentiates it in the market, appealing to clients looking for innovative approaches to biologic manufacturing. iBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iBio stock

Net Debt to EBITDA of iBio is 2.44 in 2026.

Net Debt to EBITDA of iBio changed from 0.27 to 2.44, representing a 795.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA iBio since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's iBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — iBio

All Key Metrics — iBio